Safety data sheet. GHS / OSHA HCS 2012 format, 16 sections. Issued by Epic Peptides Lab for the catalogue items listed in Section 1.

Epic Peptides Lab

Safety data sheet · capsules

Epic Peptides Lab · USA

Document number: PL-SDS-076
Revision: 1.0 · 2026-10-03

GW-501516

capsules

WARNING

1Identification

Product Identifier

GW-501516

Document Number

PL-SDS-076

Catalogue Items Covered

Id
8627
Name
GW-501516 (Cardarine) (10mg/capsule) 60 Capsules
Sku
PL-GW501516-10MG-CAP

Recommended Use

Laboratory research use by trained personnel.

Restrictions On Use

Not for human or veterinary use.

Supplier / Distributor

Epic Peptides Lab, USA

Telephone

+1 (787) 468-5291

info@epicpeptideslab.com

2Hazard(s) identification

Classification

Carcinogenicity — Category 2 — H351

Label Elements

Pictograms: GHS08
Signal: Warning
Hazard statements: H351 Suspected of causing cancer.
Precautionary statements: P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read and understood.

P280 Wear protective gloves, protective clothing and eye protection.

P308+P313 IF exposed or concerned: Get medical advice/attention.

P405 Store locked up.

P501 Dispose of contents and container to an approved waste disposal plant in accordance with local, state and federal regulations.

Signal Word

Warning

Other Hazards

No data available.

3Composition / information on ingredients

Description

Hard gelatin capsules containing the active substance blended with microcrystalline cellulose, packed in a sealed bottle.

Composition

Name
GW-501516
Full
GW501516 (Cardarine), PPAR-delta agonist
Cas
317318-70-0
Formula
C21H18F3NO3S2
Conc
2.5% w/w of capsule contents (nominal)
Qty
10 mg per capsule
Hazards
- Carcinogenicity — Category 2 — H351
Name
Microcrystalline cellulose
Full
Microcrystalline cellulose (capsule filler)
Cas
9004-34-6
Formula
(C6H10O5)n
Conc
balance of capsule contents
Name
Gelatin
Full
Gelatin (capsule shell)
Cas
9000-70-8
Conc
capsule shell

4First-aid measures

First Aid Measures

Inhalation: Move the person to fresh air and keep comfortable for breathing. If breathing is difficult or symptoms persist, call a POISON CENTER or doctor.
Skin: Take off contaminated clothing. Wash the skin with plenty of soap and water. If irritation or a rash develops, get medical advice.
Eyes: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do; continue rinsing. If eye irritation persists, get medical advice.
Ingestion: Rinse mouth. Do not induce vomiting. Call a POISON CENTER or doctor if you feel unwell.
General: If exposed or concerned, get medical advice. Show this safety data sheet to the doctor. Pregnant or nursing laboratory staff should avoid exposure.

Most Important Symptoms And Effects

No specific symptoms are known. Pharmacologically active material: systemic effects consistent with its mechanism of action are possible after accidental injection, ingestion or absorption.

Likely Routes Of Exposure

Ingestion; inhalation of dust and skin/eye contact if capsules are opened.

5Fire-fighting measures

Fire Fighting Information: Combustible organic solid; capsule contents may form combustible dust if dispersed in bulk.

6Accidental release measures

Spill And Clean Up Procedures: Collect intact capsules. Dampen any spilled powder with water, wipe up with absorbent material and place in a sealed container for disposal.

7Handling and storage

Safe Handling: Do not open or crush capsules unless required for an experiment; if capsule contents are handled as a powder, avoid generating dust and weigh inside a ventilated enclosure. Wash hands after handling.
Safe Storage: Store at room temperature (15–25 °C) in the tightly closed original container, dry and protected from light.
Storage Temperature: 15–25 °C, dry, protected from light
Incompatible Materials: Strong oxidizing agents (Cayman); strong acids/alkalis, strong oxidising/reducing agents (Tocris).

8Exposure controls / personal protection

Occupational Exposure Limits: Microcrystalline cellulose: OSHA PEL 15 mg/m³ (total dust), 5 mg/m³ (respirable fraction); ACGIH TLV 10 mg/m³ (as cellulose).

No occupational exposure limits have been established for the active ingredient(s).
Exposure Controls And PPE: No data available.

9Physical and chemical properties

Physical State

Solid

Appearance

Hard gelatin capsules containing a white to off-white powder

Properties

Odor: Characteristic (Cayman)
Ph: Not applicable (solid)
Melting: Undetermined (Cayman/Tocris); literature/ChemicalBook: 134-136 degC
Boiling: Undetermined; ChemicalBook predicted 584.5 +/- 60 degC
Flash: Not applicable (non-flammable solid); combustible organic material
Vapour: Negligible (solid)
Density: No data available (bulk density of lyophilized cake is low)
Solubility: DMF 25 mg/mL; DMF:PBS (pH 7.2) 1:2 0.5 mg/mL; DMSO 20 mg/mL; ethanol 12 mg/mL (Cayman). Tocris: soluble to 100 mM in DMSO, 50 mM in ethanol. Selleck: DMSO 91 mg/mL, ethanol 22 mg/mL, water insoluble.
Logp: Not in SDS (predicted logP ~5-6, lipophilic carboxylic acid)
Decomp: No data available; peptides decompose above about 200 °C
Other: C21H18F3NO3S2, MW 453.5; CAS 317318-70-0; 2-[2-methyl-4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]thio]phenoxy]acetic acid. Photosensitive (ChemicalBook/Sigma).

10Stability and reactivity

Stability And Reactivity

Reactivity: Stable under recommended transport/storage conditions (Tocris); no dangerous reactions known (Cayman).
Incompatible: Strong oxidizing agents (Cayman); strong acids/alkalis, strong oxidising/reducing agents (Tocris).
Decomposition: In combustion may emit toxic fumes (Tocris): carbon oxides, nitrogen oxides, sulfur oxides, hydrogen fluoride.
Conditions To Avoid: Heat, moisture (Tocris); light (photosensitive).

Conditions To Avoid

Heat, moisture (Tocris); light (photosensitive)

Incompatible Materials

No data available.

11Toxicological information

Toxicological Information: Acute toxicity, oral
No LD50 available. Cayman cites RTECS AI9105500: 'Oral TDLO 140 mg/kg/2W (intermittent) (mouse); 2,184 mg/kg/104W (intermittent) (rat)' (lowest toxic doses, not lethal doses)

Acute toxicity, dermal
No data available

Acute toxicity, inhalation
No data available

Skin corrosion/irritation
No irritant effect (Cayman); Tocris: classification criteria not met

Serious eye damage/irritation
No irritating effect (Cayman); Tocris: classification criteria not met

Respiratory or skin sensitisation
No sensitizing effects known (Cayman)

Germ cell mutagenicity
No data available

Carcinogenicity
Not listed by IARC, NTP, OSHA (Cayman, Tocris); Tocris: 'classification criteria are not met based on available data'.

Reproductive toxicity
No data available (Tocris: criteria not met). Rodent carcinogenicity studies included tumours of reproductive organs (testes, ovaries, uterus).

STOT, single exposure
No data available

STOT, repeated exposure
No data available

Aspiration hazard
No data available
Routes Of Exposure: Ingestion; inhalation of dust and skin/eye contact if capsules are opened.
Symptoms: No specific symptoms are known. Pharmacologically active material: systemic effects consistent with its mechanism of action are possible after accidental injection, ingestion or absorption.

12Ecological information

Ecological Information: Cayman: water hazard class 1 (self-assessment), slightly hazardous for water. Sigma product page: WGK 3 (highly hazardous to water). Lipophilic, fluorinated aryl-thiazole - expected persistent; no aquatic toxicity data.

13Disposal considerations

Disposal Guidance: No data available.

14Transport information

Transport Classification

Note: Not regulated as a dangerous good for transport by road (DOT 49 CFR), air (IATA/ICAO) or sea (IMDG). Not a marine pollutant. Ship refrigerated or frozen as required by Section 7; the coolant (dry ice, UN 1845) is regulated when used.

15Regulatory information

Regulatory Information

Tsca: Not listed on TSCA inventory (Cayman). R&D exemption applies to research use.
Carcinogen Listings: Not listed by IARC, NTP, OSHA; California Prop 65: not applicable (Tocris). (Rodent carcinogen per GSK studies - see notes.)
Dea: Not a DEA-controlled substance (not in the Anabolic Steroid Control Act schedules; it is a PPAR-delta agonist, not a SARM/steroid).
Other: Never approved as a drug anywhere (development abandoned 2007). FDA has issued warnings about GW501516 ('Cardarine') marketed illegally in bodybuilding products. WADA remark: GW1516/GW501516 is explicitly named on the WADA Prohibited List S4.4 (metabolic modulators, PPAR-delta agonists) and WADA issued a specific health warning (2013) because of the rodent cancer findings - remark only.

Carcinogen Listings

GW-501516 is self-classified Carc. 2 on rodent data (see above)

16Other information

Revision: October 3, 2026
Sources Consulted: Cayman Chemical

Tocris / Bio-Techne

Sigma-Aldrich

Selleck Chemicals

ChemicalBook

Spectrum Chemical

Sigachi Industries

Parchem

Fisher Scientific / Acros Organics

Electron Microscopy Sciences
Confidence: medium
Additional Information: WADA Prohibited List class S4.4; also sold as "Cardarine".

Back to SDS list